Cardiovascular co-medication among users of antiobesity drugs: A population-based study

Pharmacy World and Science

Volumn 32, Issue 6, 2010, Pages 752-758

  Amundsen, Merethe Omdal ^a   Engdahl, Bo ^b   Berg, Christian ^b   Nordeng, Hedvig ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Antidiabetic drugs; Antiobesity drugs; Cardiovascular drugs; Co medication; Norway; Prescription database

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; CARDIOVASCULAR AGENT; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADULT; AGE; AGED; ARTICLE; CHILD; CHRONIC DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORWAY; POLYPHARMACY; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; RECOMMENDED DRUG DOSE; SCHOOL CHILD; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-OBESITY AGENTS; CARDIOVASCULAR AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFANT; MALE; MIDDLE AGED; NORWAY; POLYPHARMACY; POPULATION SURVEILLANCE; YOUNG ADULT;

EID: 79952709429     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-010-9432-7     Document Type: Article

References (29)

1. WHO. Obesity and overweight. What are overweight and obesity? http://www.who.int/mediacentre/factsheets/fs311/en/index.html; 2006. Accessed 13 June 2010.
2. WHO. Obesity and overweight. http://www.who.int/hpr/NPH/docs/gs-obesity. pdf; 2003. Accessed 13 June 2010.
3. Haslam D, Sattar N, Lean M. ABC of obesity. Obesity-time to wake up. Br Med J. 2006;333:640-2.
4. Counterweight Project Team. The impact of obesity on drug prescribing in primary care. Br J Gen Pract. 2005;55:743-9.
5. van Dijk L, Otters HB, Schuit AJ. Moderately overweight and obese patients in general practice: a population based survey. BMC Fam Pract. 2006;7:43.
6. Pokras SM, Klingman D, Annunziata K, Chapnick J, Tierce J. Utilization and patient experience with obesity prescriptions in the US. Pharmacoepidemiol Drug Saf. 2008;17(Suppl 1):S142 (abstract 324).
7. Pokras SM, Klingman D, Tierce JC. Factors associated with prescription of obesity medications in the US. Pharmacoepidemiol Drug Saf. 2008;17(Suppl 1):S143 (abstract 326).
8. The Norwegian Medicines Agency. SPC - orlistat. http://www. legemiddelverket.no/custom/Preparatsok/prepSearch-80333.aspx?SearchID= 0a6afb93-7531-4c58-b8b5-586062d5c4e8. Accessed 13 June 2010.
9. The Norwegian Medicines Agency. SPC - reductil. http://www. legemiddelverket.no/custom/Preparatsok/prepSearch-80333.aspx?SearchID= a730bc6a-4b18-4e5b-9d81-a00da5aba98e. Accessed 13 June 2010.
10. Rucker D, Padwal R, Li SK, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. Br Med J. 2007;335:1194-9. (Pubitemid 350273303)
11. EMEA. European Medicines Agency recommends suspension of marketing authorizations for sibutramine. http://www.ema.europa.eu/pdfs/human/referral/ sibutramine/3940810en.pdf; 2010. Accessed 13 July 2010.
12. EMEA. SPC - Acomplia. http://www.ema.europa.eu/humandocs/PDFs/EPAR/ acomplia/H-666-PI-da.pdf. Accessed 13 June 2010.
13. EMEA. Press release. The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. http://www.emea.europa.eu/humandocs/ PDFs/EPAR/acomplia/53777708en.pdf; 2008. Accessed 13 June 2010.
14. EMEA. Questions and answers on the recommendation to suspend the marketing authorisation of Acomplia (rimonabant). http://www.emea.europa.eu/ humandocs/PDFs/EPAR/acomplia/53715308en.pdf; 2008. Accessed 13 June 2010.
15. Lægemiddelstyrelsen. Brug af receptpligtige slankelægemidler 2003-2007 [Use of prescription antiobesity drugs]. http://www. laegemiddelstyrelsen.dk/statistik/forbrugsanalyser/slankemidler/ slankemidler-notat2.asp; 2008. Accessed 13 June 2010 (in Danish).
16. Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Leufkens HG, Egberts AC, Sturkenboom MC. Cardiovascular and psychiatric risk profile and patterns of use in patients starting anti-obesity drugs. Pharmacoepidemiol Drug Saf. 2009;18:631-8.
17. Reuter. Learn about the anti-obesity treatments markets: analysis & forecasts 2009-2024. http://www.reuters.com/article/pressRelease/idUS139205?30- Mar-2009?BW20090330; 2009. Accessed 13 June 2010.
18. Rønning M, Berg CL, Furu K, Litleskare I, Sakshaug S, Strøm H. The Norwegian Prescription Database 2004-2007. Oslo: The Norwegian Institute of Public Health; 2008. ISBN:978-82-8082-253-6.
19. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2008, 11th edn. Oslo: The Norwegian Institute of Public Health; 2007. ISBN:978-82-8082-369-4.
20. Tobi H, Faber A, van den Berg PB, Drane JW, den Berg LT. Studying co-medication patterns: the impact of definitions. Pharmacoepidemiol Drug Saf. 2007;16:405-11.
21. Ulset E, Undheim R, Malterud K. Has the obesity epidemic reached Norway? Tidsskr Nor Lægeforen. 2007;127:34-7 (in Norwegian).
22. Ministry of Health and Care Services. NOU 1999: 13. Kvinners helse i Norge. Kapittel 1.9: Kjønnsperspektiv på helsetjenestetilbud og - forbruk [Womens health in Norway. Chapter 1.9: The gender perspective on health services and health services consumption] (in Norwegian).
23. Counterweight Project Team. Evaluation of the counterweight programme for obesity management in primary care: a starting point for continuous improvement. Br J Gen Pract. 2008;58:548-54.
24. Elliott RA, Ross-Degnan D, Adams AS, Safran DG, Soumerai SB. Strategies for coping in a complex world: adherence among older adults with chronic illness. J Gen Intern Med. 2007;22:805-10. (Pubitemid 46763986)
25. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care. 2003;26:1408-12. (Pubitemid 36929171)
26. Volpe M, Chin D, Paneni F. The challenge of polypharmacy in cardiovascular medicine. Fundam Clin Pharmacol. 2010;24:9-17.
27. Benner JS, Chapman RH, Petrilla AA, Tang SS, Rosenberg N, Schwartz JS. Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Am J Health Syst Pharm. 2009;66:1471-7.
28. Harder S, Saal K, Blauth E, Beyer M, Gerlach FM. Appropriateness and surveillance of medication in a cohort of diabetic patients on polypharmacy. Int J Clin Pharmacol Ther. 2009;47:104-10.
29. Linné Y, Rooth P, Rössner S. Success rate of orlistat in primary-care practice is limited by failure to follow prescribing recommendations: the referral letter content vs. clinical reality. Int J Obes Relat Metab Disord. 2003;27:1434-5. (Pubitemid 37386496)